Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma

This study is testing a CAR-T cell therapy called ECAR01 — where a patient's own immune cells are genetically engineered to recognize and destroy cancer cells — for people with certain blood cancers that have come back or stopped responding to previous treatments. The cancers include B-cell leukemia, B-cell lymphoma, and multiple myeloma. **You may be eligible if...** - You are over 3 years old - You have relapsed or treatment-resistant B-cell leukemia (B-ALL), B-cell lymphoma (including DLBCL, mantle cell, follicular, or others), or multiple myeloma - Your cancer cells express a protein called CD19 (confirmed by lab test) - You are in reasonably good health (ECOG score 0–2) - You have adequate heart, liver, lung, and kidney function - You are willing to use effective birth control **You may NOT be eligible if...** - You have had a stroke, seizure, dementia, or other significant brain event in the past 6 months - You have another active cancer besides the one being treated - You have a serious heart condition like heart failure or significant arrhythmia - You have active hepatitis B, hepatitis C, HIV, or syphilis - You have an active infection requiring IV antibiotics - You are pregnant or breastfeeding - You have a systemic autoimmune disease or immune deficiency Talk to your doctor to see if this trial is right for you.